Immune therapy targets depression by calming inflammation, early trials underway
Researchers are exploring an immune-based approach to depression, testing dupilumab (an IL-4 receptor blocker) to dampen the Th2 inflammatory pathway. Early mouse data showed reversal of depression-like symptoms, and a small clinical trial in treatment-resistant depression is planned, signaling a potential shift toward immune-targeted, personalized treatments for depression.